Abstract
The hypothesis was tested that M2-selective antagonists partially utilize the allosteric site of muscarinic M2receptors. The interactions of the allosteric agent W84 (hexane-1,6-bis[dimethyl-3′-phthalimidopropyl-ammonium bromide]) were studied with the M2/M4-selective AF-DX 384 [(±)-5,11-dihydro-11-{[(2-{2-[(dipropylamino)methyl]-1-piperidinyl}ethyl)amino]carbonyl}-6H-pyrido(2,3-b)(1,4)-benzodiazepine-6-one], the nonselective N-methylscopolamine (NMS), and a number of other muscarinic antagonists. In isolated paced guinea pig atria, the antagonistic effect of W84 against oxotremorine- and arecaidine propargyl ester-induced negative inotropic actions reached a limiting value at higher W84 concentrations, revealing negative cooperativity (factors of cooperativity α = 311 and α = 495, respectively). The antagonistic potency of W84 in this M2receptor model (W84 binding constantK A ∼ 160 nm) was higher than at M1/M4-like receptors of rabbit vas deferens (K B ∼800 nm) and at M3 receptors of guinea pig ileum (K B ∼4,000 nm). In paced atria, combinations of W84 with muscarinic antagonists yielded more-than-additive antagonistic effects against oxotremorine in case of conventional antagonists such as NMS (α = 18) but less-than-additive effects with the M2-preferring AF-DX 384 (α = 444). In guinea pig heart homogenates, the equilibrium binding of [3H]NMS was only partially inhibited by W84 (α = 2.4), whereas [3H]AF-DX 384 binding could be suppressed completely (α = 194). The difference in cooperativity reflects that W84 inhibits [3H]NMS dissociation with a ∼40-fold higher potency (ECdiss = 900 nm) than [3H]AF-DX 384 dissociation (ECdiss = 33,300 nm). [3H]NMS dissociation also could be retarded by AF-DX 384 (ECdiss = 22,000 nm), probably via an interaction with the site used by W84. The results suggest that the binding domain of AF-DX 384 partially overlaps with the common allosteric site of the M2 receptor protein.
Footnotes
- Received August 6, 1997.
- Accepted October 24, 1997.
-
Send reprint requests to: Klaus Mohr, Pharmacology & Toxicology, Institute of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany. E-mail:k.mohr{at}uni-bonn.de
-
This work was supported by the Deutsche Forschungsgemeinschaft (K.M.) and the Fonds der Chemischen Industrie (G.L.).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|